VIVUS (NASDAQ:VVUS) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.

Shares of VIVUS (NASDAQ VVUS) opened at $0.64 on Friday. The company has a market capitalization of $68.11, a price-to-earnings ratio of 1.89 and a beta of 0.77. VIVUS has a fifty-two week low of $0.61 and a fifty-two week high of $1.47. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86.

VIVUS (NASDAQ:VVUS) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.07. The business had revenue of $15.19 million for the quarter, compared to analyst estimates of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. VIVUS’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company posted ($0.09) earnings per share. analysts anticipate that VIVUS will post -0.32 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. IHT Wealth Management LLC lifted its holdings in VIVUS by 653.3% during the second quarter. IHT Wealth Management LLC now owns 1,130 shares of the biopharmaceutical company’s stock worth $1,100,000 after acquiring an additional 980 shares during the period. Bank of New York Mellon Corp lifted its holdings in VIVUS by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 3,694 shares during the period. Northern Trust Corp lifted its holdings in VIVUS by 16.8% during the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 39,473 shares during the period. Russell Investments Group Ltd. lifted its holdings in VIVUS by 84.8% during the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 68,200 shares during the period. Finally, Spark Investment Management LLC bought a new stake in VIVUS during the second quarter worth $100,000. Institutional investors and hedge funds own 31.35% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “VIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngine” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/02/vivus-vvus-rating-lowered-to-strong-sell-at-valuengine.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.